Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial-Reference-Cited by-同舟云学术

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Published:2020-03 Issue:3 Volume:145 Page:877-884
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Guttman-Yassky Emma^ORCID,Thaçi Diamant,Pangan Aileen L.,Hong H. Chih-ho,Papp Kim A.,Reich Kristian,Beck Lisa A.,Mohamed Mohamed-Eslam F.,Othman Ahmed A.,Anderson Jaclyn K.,Gu Yihua,Teixeira Henrique D.,Silverberg Jonathan I.

Funder

AbbVie Inc

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference26 articles.

1. Atopic dermatitis;Weidinger;Lancet,2016

2. Atopic dermatitis: burden of illness, quality of life, and associated complications;Drucker;Allergy Asthma Proc,2017

3. Public health burden and epidemiology of atopic dermatitis;Silverberg;Dermatol Clin,2017

4. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis;Kim;J Am Acad Dermatol,2016

5. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis;Lee;J Am Acad Dermatol,2019

Cited by 275 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis;Journal of Dermatological Treatment;2024-09

2. Januskinaseinhibitoren für dermatologische Erkrankungen;Die Dermatologie;2024-08-30

3. Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis;2024-08-27

4. Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates;Dermatology and Therapy;2024-08-22

5. Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis;Expert Opinion on Investigational Drugs;2024-08-21